Jazz reports Phase 3 success for Zepzelca in first-line maintenance for small cell lung cancer
Jazz Pharmaceuticals announced Tuesday that adding its small cell lung cancer drug Zepzelca to a maintenance treatment regimen for extensive-stage small …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
